Schrodinger, Inc.
SDGRAbout the company
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Investment snapshot
Positive
2
BUY / PASS
Neutral / negative
2 / 12
NEUTRAL / FAIL
Median fair value
$4.58
-84.5% vs price
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #2517 (Top 81.3%) | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | PASS | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | -855.7% | N/A | N/A | N/A | -385.7% | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-02-25 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-02-25 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-02-25 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-02-25 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-02-25 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-02-25 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-02-25 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-02-25 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 1✗ 27▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio6.0x✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-8.4%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-8.4%, ROC=-140.2%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)156.0x✗Dreman< 8xPrice / Book Value per Share6.0x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-4.6%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=0.6%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=6.0x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per Share174.1x✗Ackman<= 25Price vs. Trailing Low260% of trailing low ($11.36)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-2.67%; #3649/6340 (top 57.6%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.1361; #4552/6449 (top 70.6%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share6.04x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change-51.8%✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.1214; #4221/5247 (top 80.4%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-5.27%; #2998/4519 (top 66.3%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date+159.72%; #193/6202 (top 3.1%)✓OshaughnessyTop 10% of eligible cross-section - Valuation models0% pass✗ 2▾
SDGR overvalued: all 2 models price fair value below $29.53 (median $4.58)
Munger fair value$3.09✗Munger-855.7% margin vs $29.53Ackman fair value$6.08✗Ackman-385.7% margin vs $29.53 - Profitability6% pass✓ 4✗ 31▾
15 of 16 flag SDGR's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)1/8 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)1/8 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-23.3%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-65.2% (latest)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-98.7M✗BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-19.6%✗Lynch> 15%EBIT / Enterprise Value-8.4%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-8.4%, ROC=-140.2%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-14.22%✗PiotroskiROA > 0ROA Change YoY-22.73% -> -14.22% (delta: +8.51%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=1.91%, ROA=-14.22%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY63.6% -> 55.7%✗PiotroskiImproved YoYPre-Tax Income / Revenue-21.1%✗Dreman>= 8%Net Income / Shareholders' Equity-19.6%✗Dreman> 12%Margin of SafetyP/B=6.0x✗PabraiP/B < 1.5 or P/E < 15Return on Equity-21.8% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency1/7 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-49.6%✗Ackman>= 15%Net Income / Shareholders Equity-19.6%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-81.9% (2023) -> -65.2% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 64.9% -> 55.7%, operating margin -81.9% -> -65.2%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-2.67%; #3649/6340 (top 57.6%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+25.74%; #1670/3702 (top 45.1%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-19.63%; #3671/5226 (top 70.2%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.0997; #3478/5884 (top 59.1%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years1/7 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Debt & Leverage8% pass✓ 3✗ 12▾
11 of 12 flag SDGR's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest Coverage✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities2.75✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt Levels✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDA✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section - Cash Flow10% pass✓ 2✗ 10▾
9 of 10 flag SDGR's cash flow — Buffett, Lynch, Dreman +6 more
Free Cash Flow Proxy$-98.7M✗BuffettPositive and growingFCF Positive and Growing$-116.8M✗LynchPositive and growingOperating Cash Flow$13.9M✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=1.91%, ROA=-14.22%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)156.0x✗Dreman< 8xP/E or FCF YieldFCF Yield=0.6%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive2/7 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-5.4%✗Ackman>= 4%Price / FCF per Share174.1x✗Ackman<= 25Positive Operating Cash Flow frequency2/7 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-116.8M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-5.27%; #2998/4519 (top 66.3%)✗OshaughnessyTop 10% of eligible cross-section - Growth13% pass✓ 4✗ 9▾
7 of 8 flag SDGR's growth — Graham, Lynch, Dreman +4 more
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthN/A (no inventory)✓LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency1/7 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth19.7%✓Ackman>= 5%Positive EPS Growth Frequency2/5 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 64.9% -> 55.7%, operating margin -81.9% -> -65.2%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR18.8%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Verdicts13% pass✓ 2✗ 13▾
Split decision: 12 FAIL · 2 PASS · 2 NEUTRAL
Overall verdict✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2517✓PiotroskiPASS (F-Score 5)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✗TempletonFAIL (2/8)✓SleepPASS (3/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked) - Efficiency25% pass✓ 3✗ 8▾
6 of 8 flag SDGR's efficiency — Buffett, Greenblatt, Piotroski +3 more
Current Ratio2.75✓Graham>= 2.0ROIC (3-5 yr avg)✗Buffett> 10%ROIC - WACC✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-140.2%✗Greenblatt> 25%Current Ratio Change YoY3.31 -> 2.75✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.25x -> 0.35x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities2.75✓Dreman> 1.5Return on Invested Capital✗Munger> 15%ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)✗SleepROIC > 12% in a majority of years
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 1.1% of shares last year, 16.6% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.2Bcurrent | -- | -- | -- | $1.0Best. | $1.8Best. | $1.7Best. | $1.5Best. | $1.8Best. |
| Revenue | $269.2M↑5% | $64.5M↑19% | $58.9M↑8% | $58.6M↓2% | $255.9M↑23% | $207.5M↓4% | $216.7M↑20% | $181.0M↑31% | $137.9M |
| Operating Income | -$133.6M↑22% | -$26.1M↑43% | -$41.5M↑21% | -$48.8M↑4% | -$166.9M↑20% | -$209.3M↓18% | -$177.4M↓21% | -$146.8M↓32% | -$111.4M |
| Net Income | -$59.3M↑66% | -$37.7M↓15% | $6.0M↑114% | -$60.0M | -$103.3M↑45% | -$187.1M↓560% | $40.7M↑127% | -$149.2M↓49% | -$100.4M |
| EPS (Diluted) | -- | $-0.50↓11% | $0.08↑114% | $-0.81↑1% | $-1.41↑45% | $-2.57↓576% | $0.54↑126% | $-2.10↓48% | $-1.42 |
| Gross Margin | 58.5%↑1% | 59.3%↑15% | 55.1%↑15% | 50.4%↓4% | 55.7%↓12% | 63.6%↓2% | 64.9%↑16% | 55.8%↑17% | 47.6% |
| Operating Margin | -49.6%↑25% | -40.5%↑52% | -70.6%↑27% | -83.3%↑3% | -65.2%↑35% | -100.8%↓23% | -81.9%↓1% | -81.1% | -80.8% |
| ROE | -19.6%↑64% | — | — | — | -28.4%↑36% | -44.4%↓698% | 7.4%↑122% | -33.3%↓85% | -18.0% |
| Total Debt | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Shareholders' Equity | $301.8M↓6% | $301.8M↓6% | $329.0M↓4% | $313.5M↓16% | $364.1M↓14% | $421.4M↓23% | $548.6M↑22% | $447.9M↓20% | $557.1M |
| Current Ratio | 2.75↓16% | 2.75↓16% | 2.71↓18% | 2.74↓21% | 2.75↓17% | 3.31↓22% | 4.25↓13% | 4.91↓28% | 6.85 |
| Debt / Equity | — | — | — | — | — | — | — | — | — |
| Operating Cash Flow | -$112.6M↓9942% | -$47.6M↑23% | -$34.1M↑35% | -$14.8M↓110% | $13.9M↑109% | -$157.4M↓15% | -$136.7M↓14% | -$119.7M↓69% | -$70.7M |
| Free Cash Flow | -$116.8M↓3340% | -$48.9M↑22% | -$34.4M↑34% | -$17.3M↓112% | $12.5M↑108% | -$164.7M↓10% | -$150.1M↓18% | -$127.7M↓64% | -$77.8M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
SDGR vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |